Preclinical imaging is the visualization of living animals for research purposes, such as drug development. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes. Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. Broadly speaking, these imaging systems can be categorized into primarily morphological/anatomical and primarily molecular imaging techniques. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) are usually used for anatomical imaging, while optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single photon emission computed tomography (SPECT) are usually used for molecular visualizations.
Due to the COVID-19 pandemic, the global Preclinical Imaging market size is estimated to be worth US$ 1887.9 million in 2021 and is forecast to a readjusted size of US$ 3021.2 million by 2028 with a CAGR of 6.5% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Preclinical Imaging market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Preclinical Imaging landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
In 2018, the global preclinical imaging market is expected to be dominated by North America. A number of factors such as robust R&D infrastructure for life science researches, fast adoption of novel molecular imaging technologies, significant presence of pharmaceutical and biotechnology companies, and increasing preference of end users for multimodality systems are driving the growth of the preclinical imaging market in the North American region. The Asia-Pacific market is expected to grow at the highest CAGR from 2018 to 2023. This is primarily due to the continuous government support for pharmaceutical and biotechnology R&D, increasing public-private investments to support radioisotope production, rising number of translational research activities, and evolving regulatory scenario across major Asian countries.
This report focuses on Preclinical Imaging volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Preclinical Imaging market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Preclinical Imaging Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Optical Imaging Systems
Nuclear Imaging Systems
Micro-MRI Systems
Micro-Ultrasound Systems
Micro-CT Systems
Preclinical Photoacoustic Imaging Systems
Preclinical Magnetic Particle Imaging (MPI) Systems
Segment by Application
Hospitals
Diagnostics Centers
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Perkinelmer
Bruker
Fujifilm
Mediso
Milabs
MR Solutions
Aspect Imaging
Li-Cor Biosciences
Trifoil Imaging
Miltenyi Biotec